Azitra (AZTR) Stock
Clinical stage biotech company developing microbiome skin treatments. Here's the price, business snapshot, and what's worth knowing about Azitra in October 2026.
Azitra Inc (AZTR) is a small, clinical-stage biotechnology company developing microbiome-based treatments for dermatological conditions. Investors should know it is a micro-cap issuer (market capitalisation around $2.05M), which typically implies limited liquidity, higher share-price volatility and greater sensitivity to funding and trial outcomes. The company’s work focuses on harnessing skin microbes and biologics to address inflammatory and infectious skin diseases; programmes are early-stage and outcomes remain uncertain. Financial results, regulatory milestones and clinical data can substantially move the share price in either direction. This summary is educational, not investment advice: potential investors should read the company’s filings, consider the high-risk nature of micro-cap biotech, and assess whether such exposure fits their objectives and risk tolerance. Past performance is not a reliable guide to future returns, and value can fall as well as rise.
Azitra (AZTR) Stock Forecast
Analyst price target, next 12 months
$52.84
+39926.5% vs today's $0.13
Price range over the last 12 months
Close to its 12-month low
Analysts covering Azitra have a consensus 12-month target of $52.84, above the current price of $0.13.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying AZITRA's stock with a target price of $52.84, indicating strong potential growth.
Financial Health
Azitra is maintaining stable cash flow and book value, reflecting steady financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Skin Microbiome Focus
Azitra’s programmes target skin conditions using microbial and biologic approaches — an area of scientific interest, though clinical success is uncertain.
Early-stage Outcomes
Clinical data and regulatory updates can drive sharp moves in the share price; investors should expect high event-driven volatility.
Micro-cap Considerations
With a market cap around $2.05M, liquidity and financing are meaningful risks; suitable only for those comfortable with high-risk investments.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
